Immage Biotherapeutics Corp. Stock

Immage Biotherapeutics Corp. is a biotechnology company. The Company is engaged in developing cancer immunotherapy through development of cutting-edge immunotherapy candidates using bioinformatics and outsourced laboratory resources. It is focused on developing immunotherapy biologics to treat various cancers. The Company develops, markets and licenses its immunotherapy candidate for melanoma-associated antigen-A (MAGE A). The Company plans to focus on the development of immunotherapy for breast and prostate cancer. The Company focuses on developing a fusion/hybrid antigen cancer vaccine that would not only be human leukocyte antigen (HLA) free, but also be effective to all the isomers associated with MAGE A, from 1 to 11, and the identification and development of immunotherapy candidates from its intellectual property library for the preparation for human clinical trials using a viral vector construct.